New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

Feb 13 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.